SLC22A3 and neoplasm: The cytotoxic impact of cisplatin was amplified by SLC22A3 overexpression in a study assessing the influence of SLC22A3 gene expression on the survival of patients with head and neck squamous cell cancer, in which both early as well as advanced tumor patients with elevated SLC22A3 expression had enhanced survival rates following cisplatin treatment [57].